News
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...
AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition. Find out why AZN stock is a hold.
This was the ADR's second consecutive day of losses.
10d
Zacks.com on MSNAstrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to KnowAstrazeneca (AZN) closed the most recent trading day at $73.55, moving -1.17% from the previous trading session. The stock's ...
1d
Zacks.com on MSNIs Astrazeneca (AZN) a Buy as Wall Street Analysts Look Optimistic?The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...
According to Benzinga Pro, AstraZeneca's peer group average for short interest as a percentage of float is 3.86%, which means ...
1d
TipRanks on MSNAstraZeneca’s New Study on AZD5492: A Potential Game-Changer for Autoimmune DiseasesAstraZeneca has launched a Phase I clinical study titled An Open-label, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 Followi ...
Investing.com -- AstraZeneca (NASDAQ: AZN) on Monday night received accelerated approval from the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results